IM Cannabis Corp. reports developments tied to its medical cannabis platform serving patients in Israel and Germany. Company updates commonly address medical cannabis operations, regulatory and commercial positioning, operating and financial results, and the management of liquidity through note purchase agreements, convertible notes and common share purchase warrants.
Recurring IMCC news also includes Nasdaq listing-compliance notices, board and executive appointments, shareholder or governance matters, and disclosures related to material agreements and capital structure. The company’s announcements frame IM Cannabis as an international medical cannabis issuer with cross-border supply and compliance considerations in regulated cannabis markets.
IM Cannabis (Nasdaq: IMCC) closed a private placement of a US$250,000 principal amount convertible note with an institutional investor on August 7, 2026. The note carries a 10% original issue discount, bears interest at 8% per annum (rising to 14% upon default) and is not repayable in cash, with obligations settled solely through issuance of common shares upon conversion.
The conversion price is the lower of a fixed US$0.122 per share or 90% of the lowest daily VWAP over the 20 trading days before conversion, subject to a US$0.02436 floor and a 4.99% beneficial ownership cap. IM Cannabis also issued warrants to purchase up to 2,052,545 common shares at C$0.17, exercisable immediately until August 7, 2031. According to IM Cannabis, net proceeds will be used for general corporate purposes, and the company plans to file a resale registration statement on Form F-3 with the SEC.
IM Cannabis (Nasdaq: IMCC) announced that Mr. Alon Dayan has resigned from its board of directors for personal reasons. The board and management thanked him for his contributions and wished him well. IM Cannabis operates a medical cannabis platform in Israel and Germany, including import, distribution and retail pharmacy activities.
IM Cannabis (NASDAQ: IMCC) closed a US$225,000 convertible note financing with an institutional investor. The note carries an 8% annual interest rate, a 10% original issue discount, and is repayable only in common shares.
The conversion price is the lower of US$0.152 per share or 90% of the lowest 20-day VWAP, with a US$0.0303 floor and a 4.99% ownership cap. IM Cannabis also issued warrants for up to 1,483,386 shares at C$0.22, exercisable immediately until July 1, 2031. Net proceeds are earmarked for general corporate purposes, with plans to file a resale registration statement and securities subject to a four month and one day hold period.
IM Cannabis (NASDAQ: IMCC) signed a non-binding letter of intent to sell its European-focused subsidiary IMC Holdings to Slil.com Holding, controlled by CEO Oren Shuster. Slil would assume about C$10.5 million of IMC and IMC Holdings debt, subject to a definitive agreement and approvals.
IMC would retain its Israeli operations, aiming to improve working capital, cash flow and balance sheet strength while focusing on the local market and future investments.
IM Cannabis (Nasdaq: IMCC) filed a Form F-3 resale registration statement with the SEC on June 9, 2026. The filing covers 17,276,931 common shares tied to three 2026 convertible promissory notes and accompanying warrants. If declared effective, selling shareholders may resell these shares; IM Cannabis will not receive proceeds.
IM Cannabis (Nasdaq: IMCC) closed a US$225,000 convertible note financing with an institutional investor on June 3, 2026. The note carries a 10% original issue discount and 8% annual interest, rising to 14% on default, and is repayable only in common shares.
The conversion price is the lower of US$0.288 or 90% of the lowest 20-day VWAP, with a US$0.0576 floor and a 4.99% ownership cap. IM Cannabis also issued warrants for 781,250 shares at C$0.40, exercisable immediately until June 3, 2031. Net proceeds will fund general corporate purposes.
IM Cannabis (Nasdaq: IMCC) reported first quarter 2026 results for the period ended March 31, 2026. Revenue was $8.7 million, with gross profit of $1.4 million, an operating loss of $1.7 million, and a net loss of $2.5 million, or $0.38 per share.
The company reported a 22% year-over-year reduction in general and administrative expenses and highlighted ongoing cost optimization, working capital discipline, and liquidity management supported by convertible note financings during and after the quarter.
IM Cannabis (Nasdaq: IMCC) closed two convertible note financings bringing total gross proceeds to US$550,000 on May 7, 2026. The financings consist of a US$250,000 note (April 6, 2026) and a US$300,000 note (May 7, 2026), each issued at a 10% discount, with conversion into common shares and attached warrants.
Conversion prices, VWAP caps and 4.99% beneficial ownership limits apply; warrants are exercisable immediately and expire five years from issuance. Proceeds will be used for general corporate purposes and the company will file Form F-3 resale registration statements.
IM Cannabis (Nasdaq: IMCC) received a Nasdaq notice April 10, 2026, for non‑compliance with the $1.00 minimum bid price requirement under Nasdaq Rule 5550(a)(2).
The company has a 180‑day cure period to regain compliance, running through October 6, 2026, and shares will continue trading during the grace period.
IM Cannabis (Nasdaq: IMCC) reported audited 2025 results with revenue of C$54.7 million and a strong operational turnaround. Germany revenue surged >134% to C$36.3 million, representing over 66% of group revenue. Gross profit rose ~15% to C$9.7 million. Operating cash flow turned positive at C$4.7 million, and cash and restricted cash increased to C$3.3 million following financings including net proceeds of C$5.1 million.
The company also signed a non-binding LOI on March 17, 2026, to acquire 51% of Black Axe Technologies, marking a proposed strategic entry into defense and homeland security technology sectors.